Key Drivers
- Margin Recovery
- Positive Cash Flow
- Elevated Leverage
AIAI Summary
VREX is now primarily a merger-arbitrage trade: with only ~$0.43 (2.3%) upside to Teledyne's $18.90 cash offer, investors should participate only if they can underwrite closing risk, as a break would re-expose elevated inventory, margin volatility, and leverage.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin Recovery
- •Positive Cash Flow
- •Elevated Leverage
VREX's profitability and cash flow have rebounded sharply, but elevated debt, declining cash, inventory concentration, and recovery-driven valuation warrant caution.
Price Behavior
Key Price Behavior Insights:
- •Tight trading range
- •Support holding
- •Breakout absent
VREX was flat last month within $18.45–$18.54, holding support but lacking a breakout above resistance, favoring a wait-for-confirmation stance.
Sharp jump from $12.41 on 2026-08-07 to $18.46 on 2026-08-10 may reflect a corporate action or data adjustment
Sentiment & News
Key News Insights:
- •Deal investigations
- •BlackRock stake
- •Value screening
Varex's proposed $18.90-per-share Teledyne sale faces shareholder scrutiny, while BlackRock's 9.25% stake signals institutional interest.
Merger-related legal scrutiny may create near-term uncertainty, though institutional ownership provides a supportive signal
Similar Companies in Healthcare
Other companies in the same sector with AI ratings